Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy in Patients With Essential Arterial Hypertension

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension

Treatments: Drug: Other hypertensives; Drug: Micardis®

Study type: Observational

Funder types: Industry

Identifiers

NCT02202525

502.362

Details and patient eligibility

About

The main purpose of this prospective, multicentre, french observational study is to analyse the evolution of pulse pressure (PP) and to identify its prognostic factors in hypertensive patients three months after initiation of a new hypertensive therapy. The PP is defined as the difference between systolic blood pressure (SBP) and diastolic blood pressure (DBP).

Enrollment: 2,148 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients with essential arterial hypertension needing a new antihypertensive therapy
• A patient was included by the physician only if he/she had agreed after being informed about the study

Exclusion Criteria:

Trial design

2,148 participants in 1 patient group

Essential arterial hypertension

Description:

Patients with essential arterial hypertension needing a new antihypertensive therapy

Treatment:

Drug: Micardis®

Drug: Other hypertensives